Aktionsplan Cyclacel Pharmaceuticals, Inc.
Erweiterter Zeitplan
Einfaches Diagramm
Über das Unternehmen Cyclacel Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. weitere details| IPO date | 2005-11-30 |
|---|---|
| ISIN | US23254L2079 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Див.доход ао | 2.99 |
| Дивиденд ао | 0.6 |
| Сайт | https://www.cyclacel.com |
| Цена ао | 5.44 |
| Preisänderung pro Tag: | +0.2381% (4.2) |
|---|---|
| Preisänderung pro Woche: | -7.06% (4.53) |
| Preisänderung pro Monat: | -29.83% (6) |
| Preisänderung über 3 Monate: | -49.28% (8.3) |
| Preisänderung über sechs Monate: | -38.99% (6.9) |
| Preisänderung pro Jahr: | -76.15% (17.65) |
| Preisänderung über 3 Jahre: | -42.88% (7.37) |
| Preisänderung über 5 Jahre: | -35.53% (6.53) |
| Preisänderung seit Jahresbeginn: | -24.55% (5.58) |
|
|
Unterschätzung
|
Effizienz
|
|||||||||||||||||||||||||||||||||||||
Dividenden
|
Pflicht
|
Wachstumsimpuls
|
|||||||||||||||||||||||||||||||||||||
| Institutionen | Volumen | Aktie, % |
|---|---|---|
| Sound Income Strategies, LLC | 182 | 14.46 |
| UBS Group AG | 17 | 1.35 |
| Aufsicht | Berufsbezeichnung | Zahlung | Geburtsjahr |
|---|---|---|---|
| Mr. Spiro George Rombotis | President, CEO & Executive Director | 612.47k | 1959 (66 Jahre) |
| Mr. Paul McBarron | Executive VP of Finance, CFO, COO, Secretary & Executive Director | 321.61k | 1961 (64 Jahr) |
| Ms. Gill Christie | Director of Human Resources | N/A | 1957 (68 Jahre) |
| Dr. Brian Schwartz M.D. | Chief Medical Officer & Director | 53k | 1962 (63 Jahr) |
| Grace Kim | Investor Relations Executive | N/A |
Adresse: United States, Berkeley Heights. NJ, 200 Connell Drive - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.cyclacel.com
Webseite: https://www.cyclacel.com
